drug · antibody
tremelimumab
Phase 3updated 5mo agoby $AZN ASTRAZENECA PLC🔗 ChEMBL
Phase 3community read0 votes
🐶 often sniffed alongside
top 4Antibody drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 28 investigational indications.
indications
indications
NSCLC
targets
Cytotoxic T-lymphocyte protein 4
all catalysts(1)
Trials studying tremelimumab
- phase2Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC
- phase3A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)
- phase2Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors
- phase2A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma
- phase2Immunotherapy and SBRT for Metastatic Head and Neck Carcinomas
- phase3Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)
- phase2TheraSphere With Durvalumab and Tremelimumab for HCC
- phase1Cryoablation and Arterial Infusion of SD-101 in Combination With Durvalumab and Tremelimumab
News(7)
- A new immuno-oncology play raises $225M for a next-generation drugSolstice Oncology is advancing a medicine from China’s Harbour BioMed that it believes is able to address the weaknesses of drugs aimed at CTLA-4, a popular but tricky cancer immunotherapy target.biopharma_dive · 27d ago
- Solstice rises with $225M series A to advance next-gen CTLA-4 immunotherapy into phase 2Solstice Oncology has secured $225 million in series A funding to advance a next-gen immunotherapy that the biotech hopes will turn “darkness to light” for cancer care.fiercebiotech · 28d ago
- Editor’s Corner: Why an AstraZeneca-Bristol Myers Squibb merger is a bad ideaCombining the two drugmakers would trigger severe regulatory concerns and significant pipeline disruptions, cost numerous jobs, all while damaging the broader biopharma ecosystem and hurting patien…fiercebiotech · 2mo ago
- Wainua flop narrows AstraZeneca’s path to $80B goal ahead of high-risk readoutsWith a Phase 3 failure denting the rare disease drug’s prospects, AstraZeneca has little room for error as it plots a path toward its ambitious 2030 sales target.biospace · 2mo ago
- GU Cancer Experts Highlight Top Abstracts to Watch During ASCO 2026We spoke with leading voices in GU oncology to see which presentations they are most looking forward to during the 2026 ASCO Annual Meeting.onclive · 4mo ago
- OncLive Polls Reveal Picks for Top Lung Cancer Abstracts at ASCO 2026Lung cancer experts rank key abstracts of interest from the upcoming ASCO Annual Meeting on OncLive’s social media.onclive · 5mo ago
- Track the Lung Cancer Abstracts That are Gaining Attention at ASCO 2026Read on to see what data are poised to shape clinical discussions and decision-making in lung cancer at 2026 ASCO Annual Meeting in Chicago, Illinois.onclive · 5mo ago
Data sources
last refreshed 1m ago
Found something off?
comments(0)
5-min edit window · permanent after that